Data / Form D filings / Invizyne Technologies Inc
Invizyne Technologies Inc: Form D filing
Invizyne Technologies Inc, a biotechnology company in Monrovia, CA, filed a Form D with the SEC in 2024. The latest, on November 19, 2024, reports $11,718 sold of a $11,718 offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 750 ROYAL OAKS DR, Monrovia, CA, 91016
- Phone
- (626) 415-1488
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Nevada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2010788
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 19, 2024 | New notice | $11,718 | $11,718 | 2 | Nov 14, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Michael Heltzen | Executive Officer | |
| Lon Bell | Director | |
| Anthony DiGiandomenico | Director | |
| Mohammad Hayat | Executive Officer, Director | |
| James Bowie | Director | |
| Christopher Marlett | Director | |
| James Lalonde | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Nov 18, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Invizyne Technologies Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.